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ABSTRACT
Background One in three patients hospitalised due to
acute exacerbation of COPD (AECOPD) is readmitted
within 90 days. No tool has been developed speciﬁcally
in this population to predict readmission or death.
Clinicians are unable to identify patients at particular
risk, yet resources to prevent readmission are allocated
based on clinical judgement.
Methods In participating hospitals, consecutive
admissions of patients with AECOPD were identiﬁed by
screening wards and reviewing coding records. A tool to
predict 90-day readmission or death without readmission
was developed in two hospitals (the derivation cohort)
and validated in: (a) the same hospitals at a later
timeframe (internal validation cohort) and (b) four further
UK hospitals (external validation cohort). Performance
was compared with ADO, BODEX, CODEX, DOSE and
LACE scores.
Results Of 2417 patients, 936 were readmitted or died
within 90 days of discharge. The ﬁve independent
variables in the ﬁnal model were: Previous admissions,
eMRCD score, Age, Right-sided heart failure and Left-
sided heart failure (PEARL). The PEARL score was
consistently discriminative and accurate with a c-statistic
of 0.73, 0.68 and 0.70 in the derivation, internal
validation and external validation cohorts. Higher PEARL
scores were associated with a shorter time to
readmission.
Conclusions The PEARL score is a simple tool that can
effectively stratify patients’ risk of 90-day readmission or
death, which could help guide readmission avoidance
strategies within the clinical and research setting. It is
superior to other scores that have been used in this
population.
Trial registration number UKCRN ID 14214.
INTRODUCTION
Acute exacerbation of COPD (AECOPD) is one of
the most common reasons for hospital admission
and one-third of patients are readmitted within
90 days.1 2 Clinicians are poor at identifying
patients at particular risk of readmission.3 A simple
and accurate prognostic tool would help identify
those who may beneﬁt most from additional health
and social care services, and this hopefully will
translate into improved outcomes for patients and
more efﬁcient use of scarce resources. A condition-
speciﬁc score to predict this outcome following
hospitalisation for AECOPD has not been
developed.
Within the CODEX study,4 the ADO, BODEX,
CODEX and DOSE scores were all assessed for
their performance at predicting the combined
outcome of readmission or death without readmis-
sion in patients with COPD (see table 1). However,
most were originally developed to predict death
(ADO5 and BODEX6) or health status (DOSE7) and
all offer only modest prediction of readmission/
death without readmission. The performance of
CODEX was superior to the updated ADO and
BODEX score, with a trend towards better perform-
ance than DOSE, but this comparison was in the
CODEX derivation population.4 Derivation studies
bias results in favour of the derived tool, in this
instance CODEX, and so comparison in an external
validation cohort is required.
LACE8 was primarily derived to assess readmis-
sion/death without readmission in unselected emer-
gency and elective admissions, and has not been
Key messages
What is the key question?
▸ In patients admitted to hospital with an
exacerbation of COPD, what predicts 90-day
readmission or death?
What is the bottom line?
▸ The PEARL prognostic score comprises ﬁve
indices: Previous admissions, eMRCD score,
Age, Right-sided heart failure and Left-sided
heart failure, and is a consistent and accurate
predictor of 90-day readmission or death.
Why read on?
▸ Currently, postdischarge care is directed by
clinical judgement, although clinical judgement
alone is suboptimal: the PEARL score is easy to
apply at the bedside using indices that are
routinely available in all patients, accurately
risk stratiﬁes patients according to risk of
readmission and may inform postdischarge
planning in patients admitted with acute
exacerbation of COPD.
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compared with the other scores in table 1, which are more
COPD speciﬁc. It offers modest performance, and exceeds alter-
native generic scores that have undergone validation.3 9 A
generic score such as LACE is preferable to a disease-speciﬁc
score, unless the latter offers superior performance.
In common with previous studies, we selected ‘death without
readmission’ as a combined primary outcome with ‘readmis-
sion’. This is justiﬁed as patients who die without readmission
are likely to have been readmitted had the clinical deterioration
been recognised in time, and death without readmission and
readmission share similar predictors.
We selected a 90-day timeframe for our primary outcome as
this covers the high-risk period. In patients hospitalised due to
AECOPD who survive to discharge, one-third are readmitted
within 90 days2 and the risk of further exacerbation and
readmission over the 8–12 weeks postdischarge outweighs the
risk over the subsequent year.10 11 Such events are associated
with substantial risk of death, adverse qualify of life12–15 and
high healthcare costs.16
The aims of the present study were:
1. To develop and perform internal and external validation of a
tool to predict 90-day readmission or death without
readmission in patients discharged from hospital following
admission with AECOPD.
2. To assess tool performance at 30 days, and compare the new
tool with other prognostic scores (table 1) at 30 and
90 days.
METHODS
Study design and participation
The study populations comprise consecutive patients admitted
with AECOPD within the DECAF derivation17 and validation18
cohorts who survived to discharge. Initially, a prediction model
was developed in two UK hospitals (the derivation cohort); the
performance of this model was then assessed in: (a) the same
hospitals, but over a later time frame (‘internal validation
cohort’; temporal validation) and (b) four further UK hospitals
(‘external validation cohort’; temporal and geographical valid-
ation). External sites were chosen to ensure variation in COPD
prevalence, socioeconomic factors, rurality and structure of
care. This readmission study was a prespeciﬁed aim of this pro-
gramme of research.17 18
Patients in the derivation and external validation cohorts were
recruited prospectively, with review of coding records to maxi-
mise capture. In the internal validation cohort, patients were
identiﬁed retrospectively from a broad coding records search
and review of COPD assessments routinely completed by the
specialist nursing team. Patients in the derivation study were not
excluded. When collecting candidate indices researchers were
unaware of outcome. The internal and external validation
cohorts were individually powered.
Inclusion criteria were: a primary diagnosis of an exacerba-
tion of COPD; spirometric evidence of airﬂow obstruction; age
35 years or older and smoking history of 10 or more cigarette
pack-years. Exclusion criteria were: previous inclusion in the
same cohort, and any illness (other than COPD) likely to limit
survival to <1 year.
Data collection
Most sociodemographic and clinical data were collected at the
time of admission; additional indices collected up to the point
of discharge included length of stay and treatment with non-
invasive ventilation. Candidate predictors included stable demo-
graphic, clinical and functional indices, including markers of
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frailty. The 90-day readmission and mortality data were col-
lected from medical records. The selection of potential predic-
tors of readmission/death without readmission was informed by
a systematic literature search and clinical plausibility.19 Those
predictors that are not routinely assessed or available at admis-
sion were appropriately excluded to avoid bias from missing
data and to ensure both generalisability and ease of application
of the ﬁnal tool.20 21 When two or more indices were closely
related, the most appropriate was selected (collinearity—see the
Statistical methods section). Final candidate indices assessed are
shown in table 2.
In prognostic research, it is important that both the deﬁni-
tions of indices and methods of measurement are clear.21 All
sites received data collection guides, which included information
on sources of data, the deﬁnitions of diseases and terms and
time-points for collection. We assessed stable state breathlessness
using the extended MRC dyspnoea score (eMRCD). This
includes a measure of frailty (ability to wash and dress inde-
pendently).18 eMRCD assesses breathlessness ‘on a good day’
within the previous 3 months. Key differences to the traditional
tool include: (a) use of the term ‘unable to leave the house
unassisted’ as opposed to ‘house bound’; (b) division of the
most severe category into eMRCD 5a and 5b patients, depend-
ing on whether the person requires help with both washing and
dressing and (c) clear transition between levels.
Left ventricular failure (LVF) referred to a preadmission diag-
nosis based on echocardiograph as per the European Society of
Cardiology guidelines.22 Three patients had LVF conﬁrmed
by a different modality (CT cardiac angiography n=1, cardiac
MRI n=2).
For cor pulmonale, a clinical diagnosis was accepted, in the
absence of an echocardiograph. First, this allowed for a new
diagnosis of cor pulmonale at admission based on clinical assess-
ment alone, which is consistent with usual clinical practice.
Second, echocardiograph alone lacks precision to diagnose cor
pulmonale in comparison with heart catheterisation, which is
the gold standard.23 There were 193 patients who had a
diagnosis of cor pulmonale, of whom 62 had preadmission
echocardiographs showing cor pulmonale. Cor pulmonale on
echocardiograph was deﬁned as right ventricular impairment or
a raised pulmonary artery systolic pressure of 35 mm Hg or
more in association with lung disease.
Admission and readmission were deﬁned as an admission to a
hospital ward outwith the emergency department. Clinical care
was not inﬂuenced by the research team, and no additional tests
were performed.
Statistical methods
The derivation cohort was adequately powered based on the
minimum expected events per index (events per index: recom-
mended=10 or more; observed=14).24 The available popula-
tions from the DECAF internal and external validation cohorts
were individually powered on mortality. Given the higher event
rate for readmission/death without readmission, both the
internal and external validation cohorts were robustly powered,
with a sample size of 227 required for an expected sensitivity of
Table 2 Demographics and candidate predictors by cohort
Derivation Internal validation External validation p Value
Number of patients, n 824 802 791 N/A
Sociodemographic details
Female, % 54.2 56.4 51.5 0.14
Age* 72.3 (9.9) 73.1 (10.2) 72.2 (10.4) 0.14
Institutional care, % 5.2 6.0 3.0 0.013
Cigarette pack-years, n† 45 (32–60) 40 (30–56) 40 (30–60) <0.001
Preadmission details
eMRCD† 4 (3–5a) 5a (4–5a) 5a (4–5a) <0.001
One or more admissions previous year, % 48.2 40.5 56.6 <0.001
Weight loss >5%, % 21.6 11.9 18.5 <0.001
FEV1 %predicted* 44.5 (18.1) 48.4 (19.2) 43.0 (16.9) <0.001
Long-term oxygen, % 11.3 15.6 17.3 0.002
Long-term prednisolone, % 8.7 7.4 7.8 0.58
Left ventricular failure, % 7.4 10.7 12.3 0.003
Cor pulmonale, % 9.8 6.1 8.0 0.022
Diabetes, % 14.7 11.6 14.3 0.13
Chronic kidney disease, % 5.7 11.3 13.4 <0.001
Cerebrovascular disease, % 12.6 12.7 11.0 0.52
Atrial fibrillation, % 10.9 16.0 15.8 0.003
Asthma, % 5.1 7.2 10.2 <0.001
Cognitive impairment, % 4.6 4.4 5.4 0.58
Admission details
Length of stay, n† 6 (4–11) 5 (3–10) 4 (2–8) <0.001
Radiographic consolidation, % 29.9 29.7 23.0 0.004
Ineffective cough, % 9.3 9.6 3.4 <0.001
pH <7.35, % 20.3 15.0 14.5 0.14
Non-invasive ventilation treatment, % 17.8 13.7 12.6 0.011
*Mean (SD).
†Median (IQR).
p Value compares proportions, means and median values across all three groups.
eMRCD, extended MRC dyspnoea score.
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70%, an SE for this estimate of 5% and an event rate of 37%.25
Baseline population characteristics and outcome were described
using proportions, means with SDs or medians with IQRs, and
compared using Fisher’s exact test, analysis of variance and
Kruskal-Wallis test. Logistic regression models were compared
with Akaike Information Criterion (AIC).
Multiple imputation was used for predictor indices with
<20% missing data, using IBM SPSS statistics V.22 to create ﬁve
datasets and results were pooled using Rubin’s method.26 Data
were imputed using the Markov Chain Monte Carlo method,
with linear and logistic regression for continuous and categorical
indices. There was no missing data for outcome. Regression ana-
lysis between predictors and missing data supported the assump-
tion that data were missing at random.20 27 A large number of
indices (n=67) were included in the imputation model.
Multicollinearity between predictor indices was addressed28 and
indices were dichotomised or categorised by visual inspection of
the receiver operating characteristic (ROC) curve, a clinically
relevant cut-off, or a median split (see online supplementary
ﬁgure E1).17 To develop the ﬁnal model, logistic regression
using backward elimination was performed, with a probability
of 0.1 for exclusion,29 and scores were assigned based on their
regression coefﬁcients.30 As prediction is about estimation, it is
reasonable to include predictors with p values >0.05, otherwise
strong predictors that are rare may be inappropriately
excluded.20 The discrimination of the model was assessed by
measurement of the area under the ROC (AUROC) curve in
each cohort, and compared with other clinical scores (table 1)
by the method of DeLong et al with and without multiple
imputation.31
Calibration was assessed by the Hosmer-Lemeshow
goodness-of-ﬁt test,32 by comparing the full regression model to
the weighted model, and by comparing outcomes and
re-examining the score assigned to individual indices, across all
three cohorts. Kaplan-Meier and the log rank test were used for
time to events.
Analyses were performed using IBM SPSS statistics V.22 and
SigmaPlot V.12.3.
RESULTS
Missing data
Of the candidate indices shown in table 2, all had 1% or less
missing data for each cohort except for pH (derivation 6.6%,
internal validation 9.4% and external validation 16.2%), weight
loss (derivation 2.9%, internal validation 1.4%, external valid-
ation 12.4%), admissions per year (derivation 0%, internal
validation 0%, external validation 2.1%) and cough effective-
ness (derivation 0%, internal validation 0.37%, external valid-
ation 1.5%). Missing data for all indices, prognostic scores and
patients are shown in online supplementary table E1.
Patient characteristics
In the derivation, internal validation and external validation
cohorts, 824 (December 2008–June 2010), 802 (January 2012–
May 2013) and 791 (April 2013–May 2014) patients survived
to hospital discharge, of whom 309 (37.5%), 297 (37.0%) and
330 (41.7%) were readmitted or died within 90 days of dis-
charge. The population characteristics of each cohort are shown
and compared in table 2. A diverse population of patients with
AECOPD were recruited, exempliﬁed by signiﬁcant differences
between cohorts in median eMRCD score, admissions in the
previous year and proportions with LVF and cor pulmonale.
The population characteristics of individual hospitals are
described elsewhere.17 18
Development of a predictive score
The following indices were categorised: age <80 or 80+; cigar-
ette pack-years <45 or 45+; eMRCD score 1–3, 4, 5a or 5b;
FEV1 %predicted <50 or 50+; previous admissions (<2 or 2+
in the past year) and length of stay as per the LACE study (0, 1,
2, 3, 4–6, 7–13, or 14+ days).8 All candidate indices were ana-
lysed using backwards multivariate logistic regression (table 2).
Weight loss was not entered into the model due to the high rate
of missing data. Indices with high missing data rates may
provide biased estimates as the test may only be performed in
select patients; furthermore, collecting this index was labour
intensive, a problem which would likely recur in clinical
practice.29
The indices retained in the ﬁnal model were: Previous admis-
sions, eMRCD score, Age 80 or more, cor pulmonale (‘Right
ventricular failure’) and Left ventricular failure, and were col-
lectively named the PEARL score (table 3, and see online
supplementary table E2). The PEARL regression equation was
compared within the derivation cohort by AIC, entering age as
a categorical and continuous variable: PEARLage catergorical
AIC=940.4, PEARLage continuous AIC=940.8. This is the recom-
mended approach to compare the relative quality of two related
models,21 and shows no difference, supporting the categorisa-
tion of age for ease of application of the score.
As continuous variables were dichotomised, primarily to
ensure ease of use, the regression coefﬁcients (the column
entitled ‘B’ in table 3) show the relative contribution of each
Table 3 Predictors of 90-day readmission or death in the derivation cohort, the PEARL score
Derivation cohort All cohorts
PEARL indices B p Value OR (95% CI) Weighting B Updated weighting
Previous admissions (2+) 1.04 <0.001 2.84 (1.98 to 4.07) 2 1.14 3
eMRCD score 4 0.67 0.002 1.96 (1.29 to 2.98) 1 0.37 1
eMRCD score 5a 1.13 <0.001 3.10 (1.89 to 5.10) 2 0.85 2
eMRCD score 5b 2.02 <0.001 7.51 (4.17 to 13.52) 3 1.09 3
Age 80 or more 0.38 0.032 1.47 (1.03 to 2.08) 1 0.38 1
Right ventricular failure 0.50 0.050 1.66 (1.00 to 2.74) 1 0.63 1
Left ventricular failure 0.52 0.080 1.68 (0.94 to 3.00) 1 0.52 1
Constant −0.78 <0.001 0.46 (0.36 to 0.58) −0.95
Maximum PEARL score 9
Hosmer-Lemeshow statistic=0.83, Nagelkerke r2=0.21.
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index. The coefﬁcients were used to assign initial weights to
each index in the derivation cohort. There are various
approaches to adjust models to improve prediction and general-
isability27 33; this can involve combining derivation and valid-
ation data sets.27 The assigned weights were re-evaluated after
pooling all three cohorts. The original weightings assigned in
the derivation cohort were appropriate, except ‘previous admis-
sions’, which should optimally be weighted as three (table 3).
Performance and calibration of the PEARL score
The AUROC for the PEARL score for 90-day readmission/death
without readmission was: derivation=0.73 (95% CI 0.70 to
0.77); internal validation=0.68 (95% CI 0.64 to 0.72) and
external validation=0.70 (95% CI 0.66 to 0.73). In all three
cohorts combined, the AUROC for 90-day readmission/death
without readmission was 0.70 (95% CI 0.68 to 0.73). For
90-day readmission, only (not including death) the AUROC was
0.69 (95% CI 0.67 to 0.71).
The risk of readmission or postdischarge death increases with
higher PEARL scores (table 4). Further details of all cohorts,
and data on readmission and death as lone outcome are shown
in the online supplementary table E3; across all three cohorts,
risk was similar with all p values >0.05 showing that predic-
tions are consistent. We grouped scores into low-risk (0–1),
intermediate-risk (2–4) and high-risk (5+) PEARL scores.
Sensitivity and 1–speciﬁcity for the PEARL score are shown in
the online supplementary table E4. In the low-risk group
(PEARL 0–1), only 2.5% (22/890) died postdischarge within
90 days.
Calibration was further assessed by plotting ‘expected prob-
ability’ (calculated from the full regression equation) against the
‘observed probability’. Calibration tends to perform best in der-
ivation cohorts, so the derivation and validation cohorts were
plotted separately. Again, PEARL was well calibrated (perfect
calibration would fall on the 45° line; see ﬁgure 1).
Comparison with other prognostic scores
The ROC curves for each prognostic score are shown in ﬁgure 2
for the validation cohorts combined. Comparison within a der-
ivation cohort favours the developed tool, so the derivation
cohort is not included within the graph. This shows that the
ROC curve area is higher for PEARL than the other scores.
Table 5 shows the comparison between PEARL and all other
tools for each individual cohort. PEARL was superior to ADO,
BODEX, DOSE and LACE in all three cohorts, and to CODEX
within the derivation and external validation cohorts. Results
were unchanged with complete case analysis. Thirty-day com-
parisons are shown online (see online supplementary table E5).
PEARL was also superior to the original ADO score, the
eMRCD score (the strongest of the PEARL indices) and the
DECAF score (see online supplementary table E6).
Table 4 Ninety-day death or readmission probability by PEARL score
Risk PEARL score Derivation cohort, % (n) Validation cohort, % (n) All cohorts, % by risk group
Low 0 15.1 (25/166) 16.4 (29/177) 20.7 (184/890)
1 23.6 (49/208) 23.9 (81/339)
Intermediate 2 33.8 (48/142) 36.3 (116/320) 42.1 (454/1078)
3 51.2 (44/86) 41.7 (111/266)
4 59.1 (55/93) 46.8 (80/171)
High 5 65.2 (43/66) 60.1 (95/158) 66.4 (298/449)
6 67.5 (27/40) 69.2 (63/91)
7 72.2 (13/18) 70.2 (40/57)
8 100 (4/4) 77.8 (7/9)
9 100 (1/1) 100 (5/5)
Total 37.5 (309/824) 39.4 (627/1593) 38.7 (936/2417)
Figure 1 Calibration curve showing predicted risk compared with
observed risk by PEARL score.
Figure 2 Receiver operating characteristic curves for PEARL, ADO,
BODEX, CODEX, DOSE and LACE for 90-day readmission or death,
validation cohorts combined.
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Time to death or readmission, and readmission frequency
Time to death or readmission was available for 90 days in all
three cohorts and for 1 year in the derivation and internal valid-
ation cohorts. Higher PEARL risk groups were associated with a
shorter time to death or readmission (ﬁgure 3 and see online
supplementary table E7).
PEARL risk group identiﬁes those at risk of frequent admis-
sions. For risk groups 0–1, 2–4 and 5–9, the median (IQR)
number of readmission was 0 (0–1), 1 (0–2) and 2 (1–3). When
adjusted for death (time exposed to readmission), the risk was 0
(0–1.8), 1 (0–3) and 3 (1–6), respectively.
DISCUSSION
We have developed and validated a model to predict 90-day
readmission/death without readmission in patients hospitalised
with an AECOPD, the ‘PEARL score’. The tool was designed to
be easily applied at the bedside using indices routinely available
at admission, and performance was superior to alternative
scores. The risk of readmission/readmission without death was
considerably higher in the ﬁrst 90 days than during the rest of
the year, both overall and within the moderate-risk and high-risk
PEARL groups, which justiﬁes our chosen timeframe. Rates of
readmission were similar to those seen in the European
National Audit 2016.34 Our composite end point is more
appropriate than readmission alone, as the latter would include
both those who are neither readmitted nor die and those who
die without readmission in the ‘favourable’ outcome group.
Accurate risk stratiﬁcation of patients should help efﬁciently
direct resources aimed to reduce readmissions, such as sup-
ported discharge services, pulmonary rehabilitation, education
programmes and possibly azithromycin therapy, although the
impact of these strategies requires assessment. Furthermore,
identiﬁcation of patients who are at risk of death without
readmission may allow services to be put in place to facilitate
early recognition of deterioration and readmission.
The study has a number of strengths, most importantly con-
secutive recruitment of patients and high case ascertainment.
This is supported by excellent recruitment rates at all sites
which were substantially higher than the 2015 UK national
COPD audit, as detailed previously.18 Generalisability is sup-
ported by consistent performance in three cohorts, including
the prospective external validation cohort (the ‘gold standard’
for assessing performance). The six hospitals that took part had
different structures of care and varied populations, with respect
to readmission avoidance schemes, COPD prevalence, socioeco-
nomics and rurality. Furthermore, data were collected by a
variety of healthcare professionals, including physicians and spe-
cialist nurses.
The eligibility criteria were inclusive; few patients were
excluded due to poor prognosis (expected survival <1 year for
an illness other than COPD): in the internal validation cohort,
for example, this comprised only 27 patients (3.4%), principally
due to metastatic malignancy. Deﬁnitions were aligned with
usual clinical practice, and were pragmatic to reduce missing
data and the consequent risk of bias. This approach is regarded
as a key strength in prognostic research.20 21 Primary outcome
data were available in all patients, missing data rates were low
and multiple imputation and complete case analyses showed
that results were robust. Further study strengths can be seen in
the online supplement, ‘The CHARMS checklist’,21 which pro-
vides a framework to critique prognostic studies.
There are a number of limitations within the study. Most
patients in the internal validation cohort were identiﬁed
retrospectively, which may have compromised performance.
Figure 3 Time to readmission or death, by PEARL risk group: (A) in all cohorts up to 90 days, (B) in the derivation and internal validation cohort
up to 365 days (comparison using the log rank test).
Table 5 Ninety-day readmission or death, AUROC curves, with
data imputation
Prognostic
score Derivation Internal validation
External
validation
PEARL 0.73 (0.70 to 0.77) 0.68 (0.64 to 0.72) 0.70 (0.66 to 0.73)
ADO 0.67 (0.63 to 0.71)* 0.64 (0.60 to 0.67)† 0.58 (0.54 to 0.62)*
BODEX 0.65 (0.61 to 0.69)* 0.64 (0.60 to 0.68)‡ 0.62 (0.58 to 0.66)*
CODEX 0.69 (0.65 to 0.73)† 0.66 (0.63 to 0.70) NS 0.62 (0.58 to 0.66)*
DOSE 0.63 (0.59 to 0.67)* 0.59 (0.55 to 0.64)* 0.61 (0.57 to 0.65)*
LACE 0.65 (0.61 to 0.69)* 0.61 (0.57 to 0.65)† 0.65 (0.61 to 0.68)‡
AUROC curves (and 95% CIs) of each score compared with PEARL by method of
DeLong et al: *<0.001, †<0.01, ‡<0.05.
Missing data >20% for BODEX and DOSE. On complete case analysis, BODEX=0.63
(0.59–0.67), DOSE=0.60 (0.53–0.66).
NS, not significant.
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However, the risk of any consequent bias is probably low as the
relevant indices were recorded during the patients’ admission
prior to the outcome. When extracting data, researchers were
blind to outcome. Furthermore, the external validation cohort
was prospective and individually powered.
Varied rates of cor pulmonale and LVF may reﬂect inconsist-
ency in clinical assessment, or could represent true population
differences, supporting external validity. Despite variation in
rates, both were associated with readmission/death without
readmission in all three cohorts. Dichotomising continuous
indices, such as age, allows a score to be calculated at the
bedside without the full regression equation and a computer.
When this approach is adopted, concern about consequent loss
of prognostic strength may be raised. However, the impact of
dichotomising (or categorising) continuous variables on per-
formance may be minimal if the relation between the index and
risk of outcome is non-linear, and the prognostic threshold(s)
appropriately selected.20 The impact of dichotomising age on
the performance of the PEARL score was negligible. We did not
differentiate between different causes of readmission such as
respiratory or non-respiratory. This would require the deriv-
ation and validation of separate scores, and based on data from
our validation cohorts most admissions are respiratory (more
than three in four). Furthermore, differentiating between
cardiac and respiratory causes of readmission can be challen-
ging. While PEARL performed well in all cohorts, and partici-
pating units were chosen to ensure variation in population and
structure of care, conﬁrmation of performance in healthcare set-
tings outside the UK is desirable. A ﬁnal limitation, which is
common to all prognostic research, is that the strength of the
association of the predictor with the outcome may vary
between patients.35
Other prognostic research shows that accurate prediction of
readmission is challenging.9 The discrimination of PEARL
(external validation AUROC=0.70) is superior to all other tools
that predict readmission or death in AECOPD, and substantially
stronger than clinical judgement (AUROC=0.56–0.59).3 An
extensive literature search was performed to ensure the inclu-
sion of all potential predictor variables that could be easily col-
lected at the bedside. All of the indices in the PEARL score have
been previously shown to predict our outcome, except for
eMRCD score. This is important as eMRCD (along with previ-
ous admissions) was the strongest predictor. In our study, asso-
ciated pneumonia, non-invasive ventilation and institutional
care (nursing or residential home) did not appear in the ﬁnal
model. This does not mean that they are not predictors, but
rather that they did not add prognostic power to the PEARL
indices, which were stronger predictors. Furthermore, eMRCD
includes a measure of frailty which may, at least in part, capture
the risk associated with such indices. The strongest predictors of
readmission/death without readmission tended to be measures
of underlying disease severity, frailty and comorbidity rather
than measures related to the acute event. For instance, DECAF
contains eosinopoenia (a marker of acute inﬂammation/sepsis),
consolidation and acidaemia; it is an excellent predictor of acute
mortality, but not medium-term and long-term outcomes in
those who survive to discharge.
The lack of novel predictors, such as cardiac biomarkers,
neural respiratory drive,36 4 m gait speed37 and quadriceps size
by ultrasound38 may be seen as a limitation. The inclusion of
too many indices in model development risks overﬁtting and
loss of performance in the validation cohorts.20 Furthermore,
the inclusion of indices that are not routinely collected may
introduce bias as missing data are large,39 40 and any association
may be due to case selection only. For example, in our study
only 17% of patients had troponin tests performed, and levels
were not related to outcome on univariate analysis. We were
unable to capture psychological well-being, social support net-
works and treatment concordance. These variables are complex
to measure and may reduce the usability of a tool.
Previous studies have shown a relationship between anxiety
and depression and readmission,41 42 although this was not seen
in our derivation cohort (based on a preadmission clinical diag-
nosis). It is possible that an alternative approach to assessing
anxiety, such as measurement of the Hospital Anxiety and
Depression score at the point of discharge, may add predictive
information.
FEV1 is associated with exacerbations and hospital admissions
in patients with stable COPD and guides treatment,16 43 44 but
in our derivation cohort it was not an independent predictor of
the primary outcome. The better performance of FEV1 in the
derivation cohorts of tools such as ADO, BODEX, CODEX and
DOSE probably reﬂects differences in population and measured
outcome.
PEARL was superior to ADO, updated ADO, BODEX,
CODEX, DOSE and LACE. The CODEX study was developed
in a large number of hospitals, the population is clearly
described and model performance is appropriately assessed. In
its derivation study, it was superior to ADO and BODEX for
90-day readmission or death, although this comparison favours
CODEX.4 In our study, it was the second best performing tool.
LACE was developed in unselected patients, rather than those
with AECOPD,9 for 30-day (and not 90-day) outcome. Of
importance, PEARL was superior at both time-points. The
LACE score was selected for comparison as it was derived in a
well-conducted study, demonstrated better discrimination than
other generic tools and is used in some hospitals. The require-
ment to score the full Charlson Comorbidity Index limits the
bedside application of both CODEX and LACE.
A number of studies have shown positive outcomes from
interventions aimed to reduce readmission.45–47 There is room
for further research to improve outcome, particularly in
COPD.48 49 The lowest risk group (PEARL 0–1) comprise
almost a third of the population. Such risk stratiﬁcation can
inform research by excluding low-risk groups (of importance,
the risk of death alone was only 2.5% in the low risk, PEARL
0–1 group), or by using randomisation techniques that include
stratiﬁcation or minimisation by risk group.
In current practice, clinician judgement is used to identify and
target resources towards patients with a high readmission risk,
although this judgement is known to be poor.3 The PEARL
score offers robust and consistent prediction of 90-day readmis-
sion or death, and is superior to alternative tools. PEARL may
aid clinical decision-making and resource allocation, although
quantiﬁcation of the impact of PEARL in terms of cost and
patient outcomes requires further research.
Acknowledgements We are grateful to Victoria Ferguson for her input with data
management. We are thankful for the hard work of the research and clinical teams
in collecting data, including Stephen Gundry, Maureen Armstrong, Peter Fenwick,
Liz Norman and her team, Nicola Bateman, June Battram, Angela Scott-Johnson,
Valerie O’Dwyer, Karen Heslop-Marshall and her team. We thank Ross C Palmer for
the PEARL acronym. Valuable statistical advice was provided by Colin Muirhead. We
thank our expert patients, especially Therese Gibson, for their support and input
with planned implementation research trials and clinical services.
Contributors SCB designed and obtained funding for the study. CE, GJG and JS
contributed to trial design. SCB, MW, RNH, RH and SCS were primary investigators
at each site. CE collated the data, performed the statistical analysis and drafted the
manuscript. Data analysis and interpretation was supported by SCB, GJG, JS and NS.
The manuscript was redrafted by SCB, GJG, JS and CE. All authors were involved
Echevarria C, et al. Thorax 2017;0:1–8. doi:10.1136/thoraxjnl-2016-209298 7
Chronic obstructive pulmonary disease
with data acquisition, contributed to the interpretation of results and reviewed and
approved the ﬁnal manuscript.
Funding This trial was funded by the Department of Health, Breathe North appeal
and Novartis Pharmaceuticals UK, and supported by the NIHR Clinical Research
Network. The salary of CE was funded by the Northumbria NHS Foundation Trust
Teaching and Research Fellowship programme.
Competing interests None declared.
Ethics approval The study was approved by NRES Committee North East, UK (REC
reference: 12/NE/0379).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Any individuals or parties interested in accessing out
data should contact SCB.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Healthcare Commission. Clearing the air. A national study of chronic obstructive
pulmonary disease. Commission for Healthcare Audit and Inspection, 2006.
2 Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome
following admission to hospital with acute exacerbation of chronic obstructive
pulmonary disease. Thorax 2002;57:137–41.
3 Allaudeen N, Schnipper JL, Orav EJ, et al. Inability of providers to predict unplanned
readmissions. J Gen Intern Med 2011;26:771–6.
4 Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in
patients hospitalized for COPD exacerbation: the CODEX index. Chest
2014;145:972–80.
5 Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic
assessment of patients with chronic obstructive pulmonary disease: the updated
BODE index and the ADO index. Lancet 2009;374:704–11.
6 Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. Severe exacerbations
and BODE index: two independent risk factors for death in male COPD patients.
Respir Med 2009;103:692–9.
7 Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a
composite index of severity in chronic obstructive pulmonary disease: the DOSE
Index. Am J Respir Crit Care Med 2009;180:1189–95.
8 van Walraven C, Dhalla IA, Bell C, et al. Derivation and validation of an index to
predict early death or unplanned readmission after discharge from hospital to the
community. CMAJ 2010;182:551–7.
9 Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital
readmission: a systematic review. JAMA 2011;306:1688–98.
10 Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in
chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2009;179:369–74.
11 Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive
pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957–63.
12 Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of
life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 1998;157(Pt 1):1418–22.
13 Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic
bronchitis and chronic obstructive pulmonary disease: a review of the literature.
Pharmacoeconomics 2005;23:345–63.
14 Bourbeau J, Ford G, Zackon H, et al. Impact on patients’ health status following
early identiﬁcation of a COPD exacerbation. Eur Respir J 2007;30:907–13.
15 Soler-Cataluña JJ, Martínez-García MA, Roman Sánchez P, et al. Severe acute
exacerbations and mortality in patients with chronic obstructive pulmonary disease.
Thorax 2005;60:925–31.
16 Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med 2013;187:347–65.
17 Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in
exacerbations of chronic obstructive pulmonary disease. Thorax 2012;67:970–6.
18 Echevarria C, Steer J, Heslop-Marshall K, et al. Validation of the DECAF score to
predict hospital mortality in acute exacerbations of COPD. Thorax 2016;71:133–40.
19 Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for
acute exacerbations of COPD. QJM 2010;103:817–29.
20 Steyerberg E. Clinical prediction models, a practical approach to development,
validation and updating. Springer, 2009.
21 Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data
extraction for systematic reviews of prediction modelling studies: The CHARMS
checklist. PLoS Med 2014;11:e1001744.
22 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure: the Task Force for the diagnosis
and treatment of acute and chronic heart failure of the European Society of
Cardiology (ESC). Developed with the special contribution of the Heart Failure
Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
23 D’Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography
versus right heart catheterization for the assessment of pulmonary hypertension.
Int J Cardiol 2013;168:4058–62.
24 Harrell FE Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved
prognostic prediction. Stat Med 1984;3:143–52.
25 Carley S, Dosman S, Jones SR, et al. Simple nomograms to calculate sample size in
diagnostic studies. Emerg Med J 2005;22:180–1.
26 Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc 1996;91:473–89.
27 Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable
prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and
elaboration. Ann Intern Med 2015;162:W1–73.
28 Field A. Discovering statistics using SPSS. 3rd edn. London: SAGE, 2009.
29 Royston P, Moons KG, Altman DG, et al. Prognosis and prognostic research:
developing a prognostic model. BMJ 2009;338:b604.
30 Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for
clinical use: The Framingham Study risk score functions. Stat Med 2004;23:1631–60.
31 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
more correlated receiver operating characteristic curves: a nonparametric approach.
Biometrics 1988;44:837–45.
32 Hosmer DWJr, Lemesbow S. Goodness of ﬁt tests for the multiple logistic regression
model. Commun Stat 1980;9:1043–69.
33 Steyerberg EW, Borsboom GJ, van Houwelingen HC, et al. Validation and updating
of predictive logistic regression models: a study on sample size and shrinkage.
Stat Med 2004;23:2567–86.
34 Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of
hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J
2016;47:113–21.
35 Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med
2006;355:2615–7.
36 Suh ES, Mandal S, Harding R, et al. Neural respiratory drive predicts clinical
deterioration and safe discharge in exacerbations of COPD. Thorax
2015;70:1123–30.
37 Kon SS, Jones SE, Schoﬁeld SJ, et al. Gait speed and readmission following
hospitalisation for acute exacerbations of COPD: a prospective study. Thorax
2015;70:1131–7.
38 Greening NJ, Harvey-Dunstan TC, Chaplin EJ, et al. Bedside assessment of
quadriceps muscle by ultrasound after admission for acute exacerbations of chronic
respiratory disease. Am J Respir Crit Care Med 2015;192:810–16.
39 Martins CS, Rodrigues MJO, Miranda VP, et al. Prognostic value of cardiac troponin
I in patients with COPD acute exacerbation. Neth J Med 2009;67:341–9.
40 Brekke PH, Omland T, Holmedal SH, et al. Troponin T elevation and long-term
mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J
2008;31:563–70.
41 Laurin C, Moullec G, Bacon SL, et al. Impact of anxiety and depression on chronic
obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med
2012;185:918–23.
42 Pooler A, Beech R. Examining the relationship between anxiety and depression and
exacerbations of COPD which result in hospital admission: a systematic review.
Int J Chron Obstruct Pulmon Dis 2014;9:315–30.
43 Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the
2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013;42:636–46.
44 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and ﬂuticasone propionate and
survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–89.
45 Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning for the
hospitalized elderly. A randomized clinical trial. Ann Intern Med
1994;120:999–1006.
46 Coleman EA, Parry C, Chalmers S, et al. The care transitions intervention: results of
a randomized controlled trial. Arch Intern Med 2006;166:1822–8.
47 Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to
prevent the readmission of elderly patients with congestive heart failure. N Engl
J Med 1995;333:1190–5.
48 Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial
(GSuST) for patients with moderate to severe COPD: randomised controlled trial.
BMJ 2012;344:e1060.
49 Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to
prevent chronic obstructive pulmonary disease hospitalizations: a randomized,
controlled trial. Ann Intern Med 2012;156:673–83.
8 Echevarria C, et al. Thorax 2017;0:1–8. doi:10.1136/thoraxjnl-2016-209298
Chronic obstructive pulmonary disease
